Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I.

Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6.

PMID:
20167359
2.

Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis.

Zhou Y, Yuan Y, Cai RR, Huang Y, Xia WQ, Yang Y, Wang P, Wei Q, Wang SH.

Expert Opin Pharmacother. 2013 Aug;14(12):1575-84. doi: 10.1517/14656566.2013.810210.

PMID:
23826679
3.

Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.

Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P.

Clin Ther. 2007 Feb;29(2):253-60.

PMID:
17472818
4.

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK.

JAMA. 2011 Jun 22;305(24):2556-64. doi: 10.1001/jama.2011.860.

PMID:
21693744
5.

Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.

Cai R, Yuan Y, Zhou Y, Xia W, Wang P, Sun H, Yang Y, Huang R, Wang S.

PLoS One. 2014 Aug 14;9(8):e104922. doi: 10.1371/journal.pone.0104922.

6.

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D; DIAGRAM Consortium.; MAGIC Consortium.; InterAct Consortium., Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N.

Lancet. 2015 Jan 24;385(9965):351-61. doi: 10.1016/S0140-6736(14)61183-1.

7.

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.

Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW.

BMJ. 2009 Jun 30;338:b2376. doi: 10.1136/bmj.b2376. Review.

8.

Risk of incident diabetes among patients treated with statins: population based study.

Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM.

BMJ. 2013 May 23;346:f2610. doi: 10.1136/bmj.f2610. Erratum in: BMJ. 2013;347:f4356.

9.

Statin therapy and risk of developing type 2 diabetes: a meta-analysis.

Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM.

Diabetes Care. 2009 Oct;32(10):1924-9. doi: 10.2337/dc09-0738.

10.

Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.

Naci H, Brugts J, Ades T.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):390-9. doi: 10.1161/CIRCOUTCOMES.111.000071. Review.

11.

Statin-associated incident diabetes: a literature review.

Park ZH, Juska A, Dyakov D, Patel RV.

Consult Pharm. 2014;29(5):317-34. doi: 10.4140/TCP.n.2014.317. Review.

PMID:
24849689
12.

Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.

Vrecer M, Turk S, Drinovec J, Mrhar A.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):567-77.

PMID:
14692706
13.

The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.

Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, Betteridge DJ, Bhatnagar D, Bilianou E, Carmena R, Ceška R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maher V, da Silva PM, Masana L, Odawara M, Pedersen TR, Rotella CM, Salti I, Teramoto T, Tokgozoglu L, Toth PP, Valensi P, Vergès B.

Atheroscler Suppl. 2014 Jun;15(1):1-15. doi: 10.1016/j.atherosclerosissup.2014.04.001. Review.

PMID:
24840509
14.

Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk.

Izzo R, de Simone G, Trimarco V, Giudice R, De Marco M, Di Renzo G, De Luca N, Trimarco B.

Nutr Metab Cardiovasc Dis. 2013 Nov;23(11):1101-6. doi: 10.1016/j.numecd.2012.11.002.

PMID:
23419735
15.

Statins and risk of incident diabetes.

Mascitelli L, Pezzetta F, Goldstein MR.

Lancet. 2010 Jun 19;375(9732):2140-1; author reply 2141-2. doi: 10.1016/S0140-6736(10)60990-7. No abstract available.

PMID:
20609947
16.

Putting the diabetes risk due to statins in perspective: a re-evaluation using the complementary outcome.

Furuya-Kanamori L, Stone JC, Doi SA.

Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):705-8. doi: 10.1016/j.numecd.2014.02.012.

PMID:
24780516
17.

Statins and risk of incident diabetes.

McEvoy JW.

Lancet. 2010 Jun 19;375(9732):2139; author reply 2141-2. doi: 10.1016/S0140-6736(10)60985-3. No abstract available.

PMID:
20609945
18.

Statins and risk of incident diabetes.

Lubsen J.

Lancet. 2010 Jun 19;375(9732):2139; author reply 2141-2. doi: 10.1016/S0140-6736(10)60986-5. No abstract available.

PMID:
20609944
19.

Statins and risk of incident diabetes.

Sheikh K.

Lancet. 2010 Jun 19;375(9732):2139-40; author reply 2141-2. doi: 10.1016/S0140-6736(10)60987-7. No abstract available.

PMID:
20609943
20.

Statins and risk of incident diabetes.

Simpson WG.

Lancet. 2010 Jun 19;375(9732):2140; author reply 2141-2. doi: 10.1016/S0140-6736(10)60989-0. No abstract available.

PMID:
20609946
Items per page

Supplemental Content

Support Center